SCF Pharma   Report issue

For profit Phase 2 Phase 4
Founded: Quebec City Canada (2009)
Status: No NME R&D (2009)

Organization Overview

First Clinical Trial
2015
NCT02518672
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Samuel Fortin | SCF Pharma

Active Ingredients

Drugs in Phase 4 Trials (2)

docosahexaenoic acid (3 trials)

eicosapentanoic acid (4 trials)

Drugs in Phase 2 Trials (1)

efalex (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cystic Fibrosis (Phase 2)

Fibrosis (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 3